A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease
Jazyk angličtina Země Spojené arabské emiráty Médium print
Typ dokumentu časopisecké články, systematický přehled
PubMed
29768996
DOI
10.2174/0929867325666180517094023
PII: CMC-EPUB-90497
Knihovny.cz E-zdroje
- Klíčová slova
- Alzheimer’s disease, NMDA, acetylcholinesterase, butyrylcholinesterase, donepezil, inhibitor, treatment.,
- MeSH
- acetylcholinesterasa metabolismus MeSH
- Alzheimerova nemoc farmakoterapie metabolismus MeSH
- butyrylcholinesterasa metabolismus MeSH
- cholinesterasové inhibitory chemie farmakologie terapeutické užití MeSH
- donepezil chemie farmakologie terapeutické užití MeSH
- lidé MeSH
- molekulární struktura MeSH
- neuroprotektivní látky chemie farmakologie terapeutické užití MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- systematický přehled MeSH
- Názvy látek
- acetylcholinesterasa MeSH
- butyrylcholinesterasa MeSH
- cholinesterasové inhibitory MeSH
- donepezil MeSH
- neuroprotektivní látky MeSH
Alzheimer's Disease (AD) is a multifactorial progressive neurodegenerative disorder characterized by memory loss, disorientation, and gradual deterioration of intellectual capacity. Its etiology has not been elucidated yet. To date, only one therapeutic approach has been approved for the treatment of AD. The pharmacotherapy of AD has relied on noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist - memantine, and acetylcholinesterase (AChE) inhibitors (AChEIs) - tacrine, donepezil, rivastigmine and galantamine. Donepezil was able to ameliorate the symptoms related to AD mainly via AChE, but also through reduction of β-amyloid burden. This review presents the overview of donepezilrelated compounds as potential anti-AD drugs developed on the basis of cholinergic hypothesis to act as solely AChE and butyrylcholinesterase (BChE) inhibitors.
Citace poskytuje Crossref.org
